title: Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.
abstract: BACKGROUND
  Long acting antiretroviral drugs represent a promising approach for chronic treatment of HIV infection. Here, we study the efficacy and safety of albuvirtide (ABT), an HIV-1 fusion inhibitor with a half life of 11-12 days in human.
  
  
  METHODS
  ABT was evaluated in a 7-week, open-label and randomized trial, combining with LPV/r. Twenty HIV-1-infected adults were assigned to two dose groups, receiving ABT (160 or 320 mg) given weekly and LPV/r given twice daily.
  
  
  RESULTS
  At week 7, the decline of HIV-1 RNA from baseline was 1.9 (1.3-2.3) log10 and 2.2 (1.6-2.7) log10 copies/ml, and suppression of HIV-1 RNA to below 50 copies/ml was achieved in 11.1 % (1/9) and 55.6 % (5/9) patients, for the 160 and 320 mg dose group respectively.
  
  
  CONCLUSIONS
  A clear dose-efficacy correlation of ABT was demonstrated. ABT combining with LPV/r is a promising two-drug regimen to be tested in larger patient population.
authors: Beijing You'an Hospital, Capital Medical University, 100069 Beijing, People's Republic of China.
authors: Hongwei
authors: H
authors: Zhang
authors: Beijing You'an Hospital, Capital Medical University, 100069 Beijing, People's Republic of China.
authors: Ronghua
authors: R
authors: Jin
authors: Nanjing Frontier Biotechnologies Co. Ltd., 5 Qiande Road, Jiangning District, 211122 Nanjing, People's Republic of China.
authors: Cheng
authors: C
authors: Yao
authors: Beijing You'an Hospital, Capital Medical University, 100069 Beijing, People's Republic of China.
authors: Tong
authors: T
authors: Zhang
authors: Beijing You'an Hospital, Capital Medical University, 100069 Beijing, People's Republic of China.
authors: Meixia
authors: M
authors: Wang
authors: Beijing You'an Hospital, Capital Medical University, 100069 Beijing, People's Republic of China.
authors: Wei
authors: W
authors: Xia
authors: Beijing Co-CRO Medical Development Co. Ltd., Beijing, People's Republic of China.
authors: Haiyan
authors: H
authors: Peng
authors: Beijing Co-CRO Medical Development Co. Ltd., Beijing, People's Republic of China.
authors: Xiaojuan
authors: X
authors: Wang
authors: Nanjing Frontier Biotechnologies Co. Ltd., 5 Qiande Road, Jiangning District, 211122 Nanjing, People's Republic of China.
authors: Rongjian
authors: R
authors: Lu
authors: Nanjing Frontier Biotechnologies Co. Ltd., 5 Qiande Road, Jiangning District, 211122 Nanjing, People's Republic of China.
authors: Changjin
authors: C
authors: Wang
authors: Nanjing Frontier Biotechnologies Co. Ltd., 5 Qiande Road, Jiangning District, 211122 Nanjing, People's Republic of China.
authors: Dong
authors: D
authors: Xie
authors: Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai St, Fengtai Dist, 100069 Beijing, People's Republic of China.
authors: Hao
authors: H
authors: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D061466:Lopinavir / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008301:Maleimides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D023581:HIV Fusion Inhibitors; D017320:HIV Protease Inhibitors; D008301:Maleimides; D010455:Peptides; D061466:Lopinavir; C573334:albuvirtide; D019438:Ritonavir